Compare XPER & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | ELDN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 219.4M |
| IPO Year | 2021 | 2014 |
| Metric | XPER | ELDN |
|---|---|---|
| Price | $5.42 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $11.40 | $9.00 |
| AVG Volume (30 Days) | 394.7K | ★ 889.5K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,105,000.00 | N/A |
| Revenue This Year | $1.90 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.91 | $1.35 |
| 52 Week High | $8.75 | $4.49 |
| Indicator | XPER | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 34.76 |
| Support Level | $4.99 | N/A |
| Resistance Level | $5.92 | $3.14 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 27.86 | 2.37 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.